• 14 JunZug voters say yes to Metalli development plan

• 14 JunModat adds Passive DNS to its Platform Magnify, Connecting Every Signal in a Single Investigation Graph

• 14 JunCelldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting

• 14 JunMineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)

• 14 JunUpstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

• 14 JunBitcoin Meets AI Trading: AIXAlpha Launches Free AI Strategy Contracts with Daily Settlement

• 14 JunHorseWood & HorseBoost [Exclusive Report 2026] The Horse Gelatin Trick Male Enhancement Or Why Talking About Natural Vitality Supplement Horse Boost?

• 14 JunOver 100 Organizations Thank America’s Blood Donors on World Blood Donor Day

• 14 JunMenarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

• 14 JunROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Via Transportation, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VIA

• 14 JunRuvi AI (RUVI) Announces Phase 3 Has Reached 90% Sellout as Investors Race to Secure Remaining Tokens at $0.02

• 14 JunSES AI DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages SES AI Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – SES

• 14 JunMUSSO E80 Muse Sees Strong U.S. Sales Following European Breakout and MUSE Design Award Win

• 14 JunMenarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

• 14 JunLightOn Demonstrates the Flexibility of Its OCR Model by Adapting It to Arabic Through Targeted Training.

• 14 JunCelldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting